Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

CPAC shoots for $45 million: Start-up firm Compact Particle Acceleration Corp. (CPAC) plans to raise approximately $45 million in three phases to help develop a "state-of-the-art," compact, intensity-modulated proton therapy system for cancer treatment featuring a dielectric-wall accelerator, according to co-development partner and investor TomoTherapy Inc. The latter firm will contribute certain intellectual property to CPAC and has the option to acquire from CPAC rights to the medical applications of the accelerator in the future. The accelerator technology, which resulted from defense-related research at Lawrence Livermore National Laboratory, is "distinct from current particle accelerator technology in that energies of 200 MeV are expected to be achieved within a relatively compact structure that fits in a standard therapy treatment room," explains TomoTherapy, a NASDAQ-traded Madison, Wis., firm that makes the Hi Art radiation therapy system for cancer treatment. CPAC anticipates closing phase one of its fundraising effort within the next several months

You may also be interested in...



Cervical cancer assay

German diagnostics firm mtm laboratories launches its CE-marked Cervatec assay in Europe for detecting cervical cell protein biomarkers. Used with conventional Pap testing, Cervatec is more than twice as sensitive as Pap tests alone in cervical cancer screening, the firm said Feb. 5. Unlike available molecular human papillomavirus (HPV) tests such as Qiagen/Digene's Hybrid Capture, Cervatec indicates the presence of the disease, not just an elevated risk, mtm CEO Peter Pack said. The firm could not disclose whether it would seek FDA approval for the test

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel